On May 31, 2022 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, reported that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis hotel in New York, NY from June 8-10, 2022 (Press release, AC Immune, MAY 31, 2022, View Source [SID1234615274]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the fireside chat, AC Immune’s CEO Andrea Pfeifer, will provide an overview of the progress being made across the Company’s development pipeline, which includes both cutting edge-diagnostics and highly selective therapeutics that are collectively designed to shift the neurodegenerative disease treatment paradigm towards earlier diagnosis and disease prevention. Dr. Pfeifer will also outline the five additional clinical milestones the Company expects to achieve by year-end, which includes reporting top line Phase 2 results from an Alzheimer’s disease (AD) prevention trial evaluating the anti-Abeta antibody crenezumab in patients with autosomal dominant AD (expected later this quarter).

The fireside chat will take place on June 9, 2022, at 8:00 am EDT / 2:00 pm CEST. A webcast of the fireside chat will be available on the Events Page of AC Immune’s website. Following the fireside chat, a replay will be archived in the same location.